The drug, Talicia, is an oral capsule comprising two antibiotics,
amoxicillin and rifabutin, as well as omeprazole, a common treatment
for heartburn.
The Israel-based company said the drug was designed to address the
high resistance of H. pylori bacteria to current clarithromycin-based
standard-of-care therapies.
![](http://archives.lincolndailynews.com/2019/Nov/04/images/ads/current/pestcontrol_bch_termites.png)
RedHill expects to launch Talicia in the United States in the first
quarter next year.
[to top of second column] |
![](http://archives.lincolndailynews.com/2019/Nov/04/images/ads/current/farmers_grain_sda_Ffarm_daily_2015.png)
Helicobacter pylori infection affects over 50% of the population
worldwide, according to Redhill, and is one of the strongest risk
factors in the development of gastric cancer.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva and
Shinjini Ganguli)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |